Business Context and Reporting Period
This Form 8-K is filed by Zafgen, Inc. (not Larimar Therapeutics, Inc.) on March 9, 2017. The report announces the financial results for the fourth quarter and the full fiscal year ended December 31, 2016. The filing serves to incorporate a press release (Exhibit 99.1) by reference.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the referenced press release (Exhibit 99.1), which is not included in the input text.
Material Changes
The filing text does not provide specific details regarding material changes versus the prior comparable period. It only confirms the announcement of results for the period ended December 31, 2016.
Guidance, Outlook, and Risks
The text does not include specific guidance, outlook, management commentary, risks, or contingencies. It notes that the information is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, limiting its legal liability status compared to a formal filing.
Investor Verification Checklist
- Verify the correct registrant name is Zafgen, Inc., as the input metadata incorrectly listed Larimar Therapeutics, Inc.
- Review Exhibit 99.1 (the press release) to obtain actual financial figures for Q4 and FY 2016.
- Confirm the legal status of the data, as the filing explicitly states the information is "furnished" and not "filed" under Section 18 of the Exchange Act.
- Check for subsequent filings or updates regarding Zafgen, Inc., as the company may have undergone significant corporate changes post-2017.